摘要
目的观察艾迪注射液在晚期肝癌治疗中的疗效及价值评价。方法入选72例晚期肝癌病人分为二组,给予介入、支持对症治疗,治疗组加用艾迪注射液静脉点滴,完成艾迪治疗3个疗程或以上者评价疗效。结果治疗组和对照组的近期有效率分别为33.3%,13.9%,在统计学上有显著性差异(P<0.05);症状改善率分别为72.2%,52.8%;AFP下降率分别为35.7%,19.4%;生存期及介入病人的骨髓抑制和胃肠道反应等方面,治疗组均优于对照组,但统计学无显著性差异;艾迪注射液未见明显毒副作用。结论晚期肝癌病人在使用介入、对症支持处理同时加用艾迪注射液治疗,对提高近期疗效、改善症状和减少介入化疗病人的毒副反应有一定作用。
Objective To evaluate the therapeutic effect of Aidi injection for the advanced primary hepatocellular carcinoma （PHC）. Methods 72 cases of the advanced PHC were divided into two groups randomly. They were treated with interventional therapy and symptomatic treatment respectively. Aidi injection was added in the therapeutic group; The effective was evaluated after 3 or more causes of treatment. Results The short-term responses in the test group and the control group were 33.33% and 13.88%（P〈0.05） respectively, the improving rate of symptom were 33.33% and 13.88% respectively and the decent rates of AFP were 35.71% and 19.35%.Compared with the control group, the therapeutic group showed a much longer survival time and slight side effect such as marrow suppression, gastrointestinal reaction, but there were no significant difference in statistics. The patients treated with Aidi injection weren＇t appear side-effect. Conclusion Aidi injection with the interventional therapy or symptomic treatment may enhance the effective rate and reduce the side effect of chemotherapy drugs to the advanced PHC patients.Aidi injection is a useful adjuvant drug.
出处
《药品评价》
CAS
2007年第5期363-364,373,共3页
Drug Evaluation
关键词
艾迪注射液
肝肿瘤
药物治疗
Aidi injection
Liver neoplasm
drug therapy
